Single Nucleotide Polymorphism Genotyping Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (TaqMan SNP Genotyping, Massarray SNP Genotyping, SNP GeneChip Arrays, Others), By Application (Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 13.18 Billion
CAGR (2026-2031)	17.15%
Fastest Growing Segment	TaqMan SNP Genotyping
Largest Market	North America
Market Size (2031)	USD 34.07 Billion

Market Overview

The Global Single Nucleotide Polymorphism Genotyping Market will grow from USD 13.18 Billion in 2025 to USD 34.07 Billion by 2031 at a 17.15% CAGR. Single Nucleotide Polymorphism genotyping is a specialized analytical technique used to measure genetic variations at specific positions within a DNA sequence to identify markers associated with diseases or physiological traits. The market is primarily propelled by the accelerating global shift towards precision medicine and the integration of pharmacogenomics into clinical care, which necessitates precise genetic profiling for tailored treatments. According to the Personalized Medicine Coalition, in 2024, the FDA approved 18 new personalized medicines, representing 38 percent of all newly approved therapeutic molecular entities. This substantial reliance on biomarker-driven therapies underscores the critical role of genotyping technologies in modern drug development and patient stratification.

Despite these favorable conditions, the industry faces substantial hurdles regarding the management of sensitive biological information. One significant challenge that could impede market expansion is the stringent regulatory landscape concerning genetic data privacy and security. The operational complexity and high costs associated with maintaining compliance with evolving international data protection standards can create barriers to entry for smaller diagnostic laboratories and limit the widespread adoption of these services.

Key Market Drivers

Increasing investments in genomic research and biobanking are functioning as a primary catalyst for the Single Nucleotide Polymorphism genotyping market, providing the necessary capital for large-scale population studies. Governments and private entities are channeling substantial funds into biobanks to create comprehensive genetic databases, which are essential for identifying disease markers and developing precision therapies. This influx of capital directly supports the procurement of genotyping arrays and sequencing platforms required to process millions of biological samples. According to the UK Government, July 2024, in the 'UK Biobank Receives £16 Million Investment' announcement, the organization secured £16 million to upgrade its cloud infrastructure, facilitating the secure storage and analysis of its vast genomic dataset. Furthermore, the commercial scale of the sector is evident in the performance of major technology providers; according to Illumina, in February 2024, the company reported full-year 2023 revenue of $4.50 billion, underscoring the sustained global demand for high-throughput genetic analysis tools.

The rising adoption of SNP genotyping in agricultural biotechnology is simultaneously expanding the market's scope beyond human healthcare. Breeders and agricultural scientists are increasingly utilizing genotyping for marker-assisted selection to enhance crop yields, improve disease resistance, and optimize livestock traits, thereby addressing global food security challenges. This trend is supported by significant public sector funding aimed at modernizing agricultural practices through genomic innovation. According to the USDA National Institute of Food and Agriculture, December 2023, in the 'Agriculture and Food Research Initiative Competitive Grants Program' notification for the 2024 cycle, the agency announced approximately $300 million in available funding to support research priorities including plant health and animal breeding genetics. These initiatives incentivize the integration of SNP-based screening tools into standard farming and breeding protocols, driving volume growth in the agrarian segment of the market.

Download Free Sample Report

Key Market Challenges

One major challenge impeding the expansion of the Global Single Nucleotide Polymorphism (SNP) Genotyping Market is the stringent regulatory landscape concerning genetic data privacy and security. As SNP genotyping involves the analysis of highly sensitive DNA sequences to identify disease markers and physiological traits, the industry is subject to an increasingly complex web of international data protection laws, such as the GDPR in Europe and HIPAA in the United States. These regulations mandate rigorous standards for data encryption, patient consent management, and cross-border information transfer. The operational complexity and high costs associated with maintaining compliance create significant barriers to entry, particularly for smaller diagnostic laboratories and research institutions that lack the financial resources of major pharmaceutical corporations, thereby stifling broader market competition and innovation.

This regulatory burden directly hampers market growth by forcing organizations to divert substantial capital toward legal and compliance frameworks rather than research and development. The difficulty of navigating these requirements is widely felt across the sector. According to the International Association of Privacy Professionals, in 2024, only 20 percent of privacy experts reported complete confidence in their organization's ability to maintain full compliance with evolving privacy laws. This lack of certainty discourages investment in new genotyping projects and slows the rollout of precision medicine initiatives, as companies hesitate to scale operations amidst the risk of severe legal penalties and reputational damage.

Key Market Trends

The market is increasingly transitioning toward Next-Generation Sequencing (NGS) technologies, which are superseding traditional arrays by enabling the simultaneous detection of known and novel variants. This shift provides the comprehensive genomic resolution required for advanced precision medicine and complex trait analysis. The rising adoption of high-fidelity sequencing platforms further supports this trend, allowing researchers to accurately genotype difficult genomic regions that earlier technologies could not resolve. This technological shift is illustrated by recent hardware deployments; according to Pacific Biosciences, February 2025, in the 'PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results' report, the company shipped 23 Revio sequencing systems in the fourth quarter of 2024, indicating robust demand for high-throughput genomic infrastructure.

Simultaneously, the utilization of liquid biopsy for non-invasive SNP detection is fundamentally reshaping clinical diagnostics. By analyzing cell-free DNA from blood samples, this approach permits the identification of disease-associated mutations without the invasiveness of tissue biopsies, facilitating the continuous monitoring of conditions such as cancer. This capability has spurred the widespread implementation of highly sensitive genotyping assays in routine patient care. The scale of this integration is evident in service volumes; according to Natera, February 2025, in the 'Natera Reports Fourth Quarter and Full Year 2024 Financial Results' release, the company processed approximately 792,800 tests in the fourth quarter of 2024, highlighting the substantial market growth in non-invasive genetic screening applications.

Segmental Insights

The TaqMan SNP Genotyping segment is identified as the fastest-growing area within the Global Single Nucleotide Polymorphism Genotyping Market. This growth is primarily attributed to the technology’s high specificity and simplified workflow, which facilitate rapid and accurate genetic testing. Clinical laboratories and research institutions increasingly utilize this method for validating large-scale genomic data, ensuring precise disease association results. Furthermore, the extensive availability of pre-designed assays supports compliance with rigorous diagnostic standards, making it the preferred choice for pharmaceutical companies conducting drug metabolism studies and developing personalized medicine strategies.

Regional Insights

North America maintains a leading position in the global single nucleotide polymorphism genotyping market, driven by substantial investment in pharmaceutical and biotechnology research. The region benefits from robust government support for genomic studies, particularly through initiatives funded by the National Institutes of Health. Additionally, the widespread adoption of precision medicine and the presence of key industry players accelerate market expansion. Established regulatory frameworks managed by the U.S. Food and Drug Administration further streamline product approvals, ensuring a stable environment for the development and commercialization of diagnostic technologies.

Recent Developments

• In October 2024, Illumina, Inc. unveiled the MiSeq i100 Series of sequencing systems, a new line of benchtop instruments designed to enhance the speed and simplicity of next-generation sequencing. The launch introduced two systems offering room-temperature shipping for reagents and significantly reduced run times, enabling same-day results for various genomic applications. While primarily a sequencing platform, the system supports a range of workflows crucial to the genotyping market, such as small genome sequencing and targeted gene panels. The company emphasized that this development would make advanced genomic analysis, including variant detection, more accessible to laboratories with limited specialized expertise.
• In September 2024, Qiagen N.V. announced the launch of more than 100 new validated assays for its QIAcuity digital PCR system. These additions to the company's portfolio were designed to address critical needs in cancer research, inherited genetic disorders, and infectious disease surveillance. The new offerings included specific assays for detecting mutations and copy number variations, which are fundamental to accurate single nucleotide polymorphism genotyping. These assays were made available through the company’s GeneGlobe platform, enabling researchers to customize their analysis and access a vast database of biological targets for precise genomic profiling.
• In February 2024, Standard BioTools Inc. entered into a strategic partnership with Next Gen Diagnostics to automate sample preparation for pathogen whole genome sequencing. Under this exclusive agreement, the company agreed to manufacture a customized version of its Biomark X9 System, a high-throughput microfluidics platform widely used for genotyping and real-time PCR applications. The collaboration aimed to leverage the company’s proprietary microfluidics technology to reduce the cost and complexity of library preparation. This partnership underscored the versatility of the Biomark X9 system, extending its utility beyond traditional genotyping to support broader genomic workflows in clinical microbiology.
• In January 2024, Thermo Fisher Scientific launched the Axiom PangenomiX Array, a high-throughput genotyping solution designed to support population-scale disease studies and pharmacogenomics research. The product was introduced as the company’s most ethnically diverse array, incorporating genomic data from diverse human populations to improve the accuracy of disease risk prediction models. It combined four distinct assays into a single test, enabling simultaneous single nucleotide polymorphism genotyping, whole genome copy number variant detection, and blood typing. This launch addressed the growing need for inclusive genomic datasets to advance precision medicine and improve health outcomes across diverse global communities.

Key Market Players

• Agilent Technologies Inc.
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• Douglas Scientific LLC
• Illumina Inc.
• Life Technologies Corp.
• Luminex Corp
• Promega Corporation
• Thermo Fischer Scientific Inc.
• Fluidigm Corporation

By Technology	By Application	By Region
TaqMan SNP Genotyping Massarray SNP Genotyping SNP GeneChip Arrays Others	Animal Genetics Plant Improvement Diagnostic Research Pharmaceuticals and Pharmacogenomics Agricultural Biotechnology Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Single Nucleotide Polymorphism Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Single Nucleotide Polymorphism Genotyping Market , By Technology:

• TaqMan SNP Genotyping
• Massarray SNP Genotyping
• SNP GeneChip Arrays
• Others

• Single Nucleotide Polymorphism Genotyping Market , By Application:

• Animal Genetics
• Plant Improvement
• Diagnostic Research
• Pharmaceuticals and Pharmacogenomics
• Agricultural Biotechnology
• Others

• Single Nucleotide Polymorphism Genotyping Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE